Prospective, Randomized Clincal Trial Comparing the Efficacy of Two Vaccines Against Hepatis B Virus (HBV) in Inflamatory Bowel Disease (IBD) Patients

被引：0
|
作者：
Chaparro, Maria
Gordillo, Jordi
Domenech, Eugeni
Esteve, Maria
Acosta, Manuel Barreiro-de
Villoria, Albert
Flores, Eva Iglesias
Blasi, Mercedes
Naves, Juan E.
Benitez, Olga
Nieto, Laura
Calvet, Xavier
Garcia-Sanchez, Valle
Villagrasa, Jose R.
Marin, Alicia C.
Ramas, Mercedes
Moreno, Isabel
Gisbert, Javier P.
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1267
引用
收藏
页码：S276 / S276
页数：1
相关论文
共 34 条
  • [31] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2014, 15
  • [32] Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Nathan R. Hill
    Daniel Lasserson
    Ben Thompson
    Rafael Perera-Salazar
    Jane Wolstenholme
    Peter Bower
    Thomas Blakeman
    David Fitzmaurice
    Paul Little
    Gene Feder
    Nadeem Qureshi
    Maarten Taal
    Jonathan Townend
    Charles Ferro
    Richard McManus
    F. D. Richard Hobbs
    Trials, 23
  • [33] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2014, 15 (01)
  • [34] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (vol 15, 160, 2014)
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2022, 23 (01)
1234